Pharmaceuticals and Healthcare - Specialty & Generic Drug Manufacturing
Strategic Profile
The vast majority of Eisai's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies to expand its research, development, manufacturing, and marketing capabilities. The stock trades at a trailing P/E of 31.8x, above the 15.4x average for the Japanese pharmaceuticals industry.
Cyborg Score Rationale
Q3 2026 revenue reached ¥219.9 billion with net income of ¥17,178 million, showing recent profitability strength. However, trailing 12-month EPS has averaged a 6.4% annual decline over the past five years, and the premium valuation presents execution risk.
Top Insights
Net margin at 5.3% on ¥808.2b of revenue indicates vulnerability to drug pricing or competitive pressure
Trading at 31.8x P/E versus 20.8x for peer average reflects market optimism on future growth
Core franchise areas in neurology and oncology with LEQEMBI (Alzheimer's) as breakthrough product providing growth catalyst
Company also operates consumer healthcare business in Japan providing diversification
Named Competitors
Takeda — Larger Japanese pharma with diversified portfolio
Bristol Myers Squibb — Strategic oncology partner for Eisai
Merck — Oncology and neurology competitor
Pfizer — Global pharmaceutical leader with oncology focus
Recent Developments
(Feb 2026) Q3 2026 revenue of ¥219.9 billion with ¥17,178 million net income shows quarterly strength
(Aug 2025) Strategic investment in Seed Therapeutics reflects ongoing biotech partnerships for innovation
(Jun 2023) Ransomware attack caused shutdown of logistical systems but appears to have been managed
Open the full interactive Eisai Co., Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.